BI0PHARMA STOCK ALERT: SUNSHINE BIOPHARMA (OTCBB: SBFM) REPORTS SUBMISSION OF AN Adva-27a MANUSCRIPT FOR PUBLICATION IN A PEER-REVIEWED SCIENTIFIC JOURNAL

Montreal, Quebec, Canada - August 15, 2012 (Investorideas.com Newswire) Sunshine Biopharma Inc. (OTCBB:SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has submitted a manuscript detailing Adva-27a preclinical research results for publication in a peer-reviewed scientific journal. Adva-27a is Sunshine Biopharma’s lead anti-cancer compound which has been shown to be effective at killing multidrug resistant cancer cells in vitro. Multidrug resistant cancer cells do not respond to any of the chemotherapy drugs currently in use for cancer treatment.

The manuscript, which was prepared by Sunshine Biopharma scientists in collaboration with scientists from Binghamton University in New York and from Ecole Polytechnique in Montreal ( Canada), contains a substantial amount of data compiled from experiments conducted by these scientists.
About Sunshine Biopharma Inc. ( OTCBB: SBFM ):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Recent Q&A with Mr. Camille Sebaaly, CFO of Sunshine Biopharma Inc. ( OTCBB: SBFM ) at Investorideas.com
http://www.investorideas.com/CO/SBFM/news/2012/07021.asp
Recent CFA commentary:
http://www.investorideas.com/CO/SBFM/news/2012/07301.asp
Published at Investorideas.com Newswire
Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 www.Investorideas.com

OTC Healthcare Stock Alert: Comprehensive Care (OTCBB: CHCR) Six Month Financial Results; Revenues of $36 Million, Earnings of $1.7 Million or $0.02 Per Share

TAMPA, Fla. - August 14, 2012 (Investorideas.com newswire) OTC Healthcare stock alert - Comprehensive Care Corporation (OTCBB: CHCR), a leading behavioral health, substance abuse and psychotropic pharmacy management services provider for managed care companies throughout the U.S., reports earnings of $1.7 million for the six months ended June 30, 2012. Earnings per diluted common share were $0.02. This compares to a $3.9 million loss in the first six months of 2011 and a $.07 loss per common share.

The Company announced that operating income for the first half of 2012 totaled $2.1 million compared to an operating loss of $3.1 million in the same period in 2011. While revenues for the first six months declined slightly from $36.8 million in 2011 to $36.0 million in 2012, the cost of revenues decreased 13.9 percent from $35.3 million in 2011 to $30.4 million in the comparable period in 2012.
"The cost saving measures we accomplished earlier this year, with mid-level and senior executives taking salary reductions, and some layoffs, combined with ending contracts that were not profitable for CompCare, are paying rewards. For the first six months of 2012, we were profitable, cash flow positive and were able to increase operating income and reduce our general and administrative expenses from $4.1 million in the first half of 2011 to $2.7 million for the comparable period this year," said Clark Marcus, Chairman and CEO.
"I am especially pleased that our pharmacy management contracts were up 18.9 percent, or $3.1 million, to $19.4 million in the first six months of 2012 compared to the previous year due to a 3.6 percent increase in membership and an 11 percent contract rate increase with the health plan we serve in Puerto Rico. We truly believe our strategies to reduce pharmaceutical costs for our clients will be a key element for our future growth," Mr. Marcus said.
"I am very proud of these financial results and the fact that CompCare's management team has solidified the foundation of the Company, improving it to support our growth. We have added senior level consultants with track records of success and we are dedicated to provide our shareholders continued growth in the future," Mr. Marcus concluded.
About CompCare:
Established in 1969, CompCare provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the ability of CompCare to maximize its market share with new pharmacy initiatives, the ability of CompCare and its staff to execute its business plan, the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, of our capitated contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, increased outsourcing of behavioral health services, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
940.262.3584
Published at Investorideas.com Newswire
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Healthcare Stock News: Comprehensive Care Corporation (OTCBB: CHCR) Announces Profitable Six Month Financial Results

TAMPA, Fla. - August 13, 2012 (Investorideas.com newswire) Comprehensive Care Corporation ("CompCare" or the "Company") (OTCBB: CHCR), a leading behavioral health, substance abuse and psychotropic pharmacy management services provider for managed care companies throughout the U.S., today announced earnings of $1.7 million for the six months ended June 30, 2012. Earnings per diluted common share were $0.02. This compares to a $3.9 million loss in the first six months of 2011 and a $.07 loss per common share.

The Company announced that operating income for the first half of 2012 totaled $2.1 million compared to an operating loss of $3.1 million in the same period in 2011. While revenues for the first six months declined slightly from $36.8 million in 2011 to $36.0 million in 2012, the cost of revenues decreased 13.9 percent from $35.3 million in 2011 to $30.4 million in the comparable period in 2012.
"The cost saving measures we accomplished earlier this year, with mid-level and senior executives taking salary reductions, and some layoffs, combined with ending contracts that were not profitable for CompCare, are paying rewards. For the first six months of 2012, we were profitable, cash flow positive and were able to increase operating income and reduce our general and administrative expenses from $4.1 million in the first half of 2011 to $2.7 million for the comparable period this year," said Clark Marcus, Chairman and CEO.
"I am especially pleased that our pharmacy management contracts were up 18.9 percent, or $3.1 million, to $19.4 million in the first six months of 2012 compared to the previous year due to a 3.6 percent increase in membership and an 11 percent contract rate increase with the health plan we serve in Puerto Rico. We truly believe our strategies to reduce pharmaceutical costs for our clients will be a key element for our future growth," Mr. Marcus said.
"I am very proud of these financial results and the fact that CompCare's management team has solidified the foundation of the Company, improving it to support our growth. We have added senior level consultants with track records of success and we are dedicated to provide our shareholders continued growth in the future," Mr. Marcus concluded.
About CompCare:
Established in 1969, CompCare provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the ability of CompCare to maximize its market share with new pharmacy initiatives, the ability of CompCare and its staff to execute its business plan, the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, of our capitated contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, increased outsourcing of behavioral health services, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
940.262.3584

Published at Investorideas.com Newswire

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Announces Expanded Access to Hemopurifier® Therapy For Individuals Infected with Hepatitis C Virus (HCV)

SAN DIEGO - August 9, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has agreed to establish a treatment program that will provide HCV-infected individuals with expanded access to Hemopurifier® therapy. The program is being initiated with support from the Institutional Review Board at the Medanta Medicity Institute (Medicity) to allow compassionate usage of the Aethlon Hemopurifier® for individuals who previously failed or subsequently relapsed standard-of-care drug regimens.

In addition to offering Hemopurifier® therapy to the citizens of India, HCV-infected individuals from the United States, European Union and other regions of the world may pursue treatment through the expanded access program. Details related to treatment protocol, inclusion criteria, patient approval processes and therapy pricing are anticipated in September. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation.
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of HCV from the entire circulatory system to improve benefit, dose, duration and tolerability of drug therapies. The Medicity is a $360 million multi-specialty medical institute established to be a premier center for medical tourism in India.
"The Medicity access program represents an important milestone in our quest to establish the selective therapeutic filtration industry," stated Aethlon Chairman and CEO, Jim Joyce. "Beyond helping HCV-infected individuals overcome their disease, we now have the opportunity to augment our established government contract revenues with Hemopurifier® product sales."
Aethlon also disclosed that it will continue conducting a study at the Medicity that is evaluating the capability of the Aethlon Hemopurifier® to accelerate HCV RNA depletion at the outset of standard of care peginterferon+ribavirin (PR) therapy. Specifically, HCV-infected individuals are enrolled to receive up to three, six-hour Hemopurifier® treatments during the first three days of PR drug therapy. Last week, Aethlon reported that the two most recent HCV infected patients to receive Hemopurifier® therapy in combination with PR drug therapy achieved undetectable viral load at day-7, which is rarely reported in drug therapy alone.
The primary clinical endpoint of the Medicity protocol has been to increase the incidence of rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts treatment cure, otherwise known as sustained virologic response (SVR), defined as undetectable HCV RNA 24-weeks after the completion of PR drug therapy. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only 10.35% (n=318/3070) of PR treated patients achieved a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. While the incidence of undetectable HCV RNA at day-7 is not reported in the IDEAL study, the study did reveal that just 4.3% (n=131/3070) of patients achieved undetectable HCV RNA at day-14, which equated to a 91% (n=118/131) SVR rate.
Aethlon reported that Hemopurifier® therapy has been well tolerated and without device-related adverse events in ten treated patients. Of these ten patients, seven patients were infected with HCV genotype-1; two patients were infected with HCV genotype-3; and one patient was infected with HCV genotype-5. At present, undetectable HCV RNA is reported in eight of the 10 treated patients. Of the two patients with detectable HCV RNA, one discontinued PR therapy as a result of a diabetes related condition. HCV RNA is undetectable in all patients (n=4) that have been monitored for 48 weeks since receiving Hemopurifier® therapy. Among the 10 treated patients, Aethlon reported that six genotype-1 patients received the three treatment Hemopurifier® protocol, which resulted in four (67%) patients achieving a RVR. The IDEAL study predicts it would normally require approximately 40 PR treated patients to achieve 4 RVR outcomes. Both patients who achieved undetectable HCV RNA at day-7 also achieved a RVR. Beyond the high likelihood of a SVR, genotype-1 patients that achieve a RVR also have the opportunity to reduce the duration of PR drug therapy from 48 weeks to 24 weeks.
In addition to expanding access to Hemopurifier® therapy at the Medicity, Aethlon is preparing to resubmit to the FDA an investigational device exemption (IDE), which will incorporate the Medicity data in an effort to gain approval to initiate HCV clinical programs in the United States.

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Biodefense Stock News; Northrop Grumman (NYSE:NOC) and PositiveID (OTCBB: PSID) Prepare for BioWatch Procurement

New York, New York - August 6, 2012 (Investorideas.com newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a news alert for biodefense stocks, PositiveID Corporation (OTCBB: PSID) and Northrop Grumman Corporation (NYSE:NOC) as both companies prepare for technology acquisitions and procurement for BioWatch Generation 3 this fall.

PositiveID Corporation (OTCBB: PSID) recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3,  a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.
In July Northrop Grumman Corporation (NYSE:NOC) reported  that its Next Generation Automated Detection System (NG-ADS) for homeland defense applications has successfully completed a rigorous field test and is ready for the program's next phase.
The NG-ADS technology is a competitor for the Department of Homeland Security's (DHS) upcoming BioWatch Gen-3 Phase II acquisition. The program seeks to deploy a nationwide network of fully autonomous bio-detectors in major metropolitan areas across the United States to provide early warning of a biological attack. DHS recently announced that a request for proposals will be issued later this year.
As a fully automated biological detection system, the NG-ADS continuously collects air samples, analyzes the samples for the presence of multiple biological pathogens, and automatically reports results to public health officials multiple times each day through a secure data network. More than 20,000 samples were collected and analyzed during the recent field test in a variety of indoor and outdoor locations in a major city in the United States .
"There are concerns that our nation won't be ready to respond should a biological attack occur," said Dave Tilles, director of Homeland Security programs at Northrop Grumman's Electronic Systems sector. "Early warning provided by an automated detection system such as the NG-ADS will allow the nation's public health and public safety officials to proactively manage the response to a biological event to reduce exposure and treat the affected population to minimize casualties."
Since the successful field test, additional improvements have been made to the NG-ADS to enhance the system's performance while reducing its life-cycle cost. The proven, life-saving capability of the NG-ADS draws upon Northrop Grumman's decade long experience developing, testing, deploying, and operating bio-detection systems for the U.S. government and other customers.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America 's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. www.PositiveIDCorp.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Read Investorideas.com on Linkedin.com/today
http://www.linkedin.com/today/investorideas.com
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation  compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and  company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com:
Contact: 800 665 0411

Healthcare and Medical Stock News: Comprehensive Care Corporation (OTCBB: CHCR) Names Colonel Ramon Martinez Senior Management Advisor To Maximize its Market Share with New Pharmacy Initiatives

TAMPA, Fla. - August 2, 2012 (Investorideas.com newswire) Comprehensive Care Corporation ("CompCare" or the "Company") (OTCBB: CHCR), which provides behavioral health, substance abuse and psychotropic pharmacy management services, has retained Ramon Martinez, a U.S. Air Force Lieutenant Colonel, retired, and leading figure in public management at state, national and international levels, as senior advisor to the Company's management. Colonel Martinez will spearhead the development and implementation of a Company mission, vision and strategy design, integrating the Company's behavioral health program with its innovative pharmacy cost containment program. The goal of this initiative is to maximize the Company's market share in both behavioral health and pharmacy management.

"An integral part of the Company's newly designed pharmacy program is the retaining of top-tiered senior advisors to assist the Company in this growth initiative," said Clark A. Marcus, Chairman and CEO. "Management believes that by attracting senior-level business executives to work with our senior management team as advisors, we enhance our ability to reach out to and attract the type of accounts who ultimately benefit the most from the Company's pharmacy cost-containment program."
"We are delighted to have Colonel Martinez join us as the first member of our team of senior advisors," continued Mr. Marcus. "Colonel Martinez's military and public sector background brings a wealth of experience to the Company, and we look forward to having him share with us his creative ideas and vision as to how we might even better enhance our pharmacy initiative. We will also look forward to working with Colonel Martinez in enlarging the scope of the market for our pharmacy initiative beyond that already contemplated by the Company."
Colonel Martinez served a twenty-year military career in the regular component of the US Air Force, climbing the ranks to become Combat Crew Commander, Test Director and Program Manager of Inter-Continental Ballistic Missiles; Assistant Professor of Philosophy at the US Air Force Academy; Deputy Secretary of the Inter-American Defense Board; US National Defense Fellow; Chief of Latin American Strategy of US Southern Command; and Interim Director of the US Southern Command Washington Field Office. He currently serves as senior consultant for XTek Solutions, a national and international consulting firm that uses advanced techniques to empower customers to sustain healthy growth.
Colonel Martinez earned a Master of Arts degree in philosophy from the University of California at Santa Barbara, a Master's degree in public administration from the University of Northern Colorado, and a Bachelor of Arts degree in philosophy and geography from California State University at Long Beach.
Colonel Martinez entered the private sector as Vice President at Genetics & IVF Institute in Fairfax, VA, later served as Assistant Director of Strategic Planning at the South Florida Workforce Board, adjunct professor of philosophy at Miami-Dade Community College, and as a consultant working on Homeland Security issues. He also served as president/CEO of Progreso Latino, Inc., the state of Rhode Island's flagship Latino empowerment agency and largest bilingual, multi-cultural community based organization.
Colonel Martinez is recipient of the Hispanic American Chamber of Commerce of Rhode Island Community Leader of 2009; National Association for the Advancement of Colored People (NAACP) Providence Branch Thurgood Marshall Award of 2008; 2008 Service Person of the Year Award of Sigma Nu Chapter Omega Psi Phi Fraternity, Inc. and The Providence Phoenix Newspaper Local Hero of 2008. He is vice chair and co-founder of the Board of Directors of the Rhode Island Mayoral Academies, and was lauded by the US Secretary of Education as a nationally unique paradigm for public education excellence with a mayor-led regional network of public charter schools serving underserved students. He served as a Trustee of Women and Infants Hospital and the Board of Directors of Clinica Esperanza/Hope Clinic, a free health clinic for the uninsured and underinsured of Rhode Island.
Colonel Martinez said, "Effective behavioral healthcare and pharmacy services are considered two crucial issues that currently impact the overall well-being of consumers and the healthcare economy as a whole. I became interested in CompCare because of its unique operating model designed to address these issues and mutually benefit health plans, self-insured companies and individuals. I am excited to leverage my skills to support CompCare in becoming a thriving, resilient company that delivers on the value promised to its customers. I am also excited to be working with a highly experienced management team who are committed to driving CompCare's growth and competitive market edge. My goal is to work with the management team to introduce a resonating mission, guiding principles, and corporate strategy that propel the Company to the next level."
About CompCare:
Established in 1969, CompCare provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the ability of CompCare to maximize its market share with new pharmacy initiatives, the ability of CompCare and its staff to execute its business plan, the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, of our capitated contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, increased outsourcing of behavioral health services, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.

Published at www.investorideas.com newswire

Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas.com and its SMS partner Running Bull OTC have been compensated by HRDN for one month of news, email and sms: twenty five thousand
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech and Pharma Stock News: BUYINS.NET Issues Sunshine Biopharma SqueezeTrigger Report

NEWPORT BEACH, Calif. - August 2, 2012 (Investorideas.com Newswire, Biotechindustrystocks.com) BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Sunshine Biopharma (OTC: SBFM) after releasing the latest short sale data through July 31, 2012. The total aggregate number of shares shorted since January 2010 is approximately 3.97 million shares. Approximately 40.11% of daily trading volume is short selling. The SqueezeTrigger price for all SBFM shares shorted is $0.47. A short squeeze is expected to begin when SBFM closes above its $0.47 SqueezeTrigger Price.

Click here to view Report: http://www.buyins.com/ reports/sbfm8-1-12.pdf
Click here for SqueezeTrigger: http://www.buyins.com/ images/sbfmstr8-1-12.jpg
Click here for Friction Factor: http://www.buyins.com/ images/sbfmff8-1-12.jpg
Friction Factor calculates if a fair market is being made in the shares of SBFM. 41% of the previous 37 trading days have been positive or bullish-biased and 59% have been negative or bearish-biased.
Regulation SHO requires bona-fide market-making activities to include making purchases and sales in roughly comparable amounts. The SEC has stated that bona-fide market-making DOES NOT include activity that is related to speculative selling strategies or investment purposes of the broker-dealer and is disproportionate to the usual market making patterns or practices of the broker-dealer in that security. Likewise, where a market-maker posts continually at or near the best offer, but does not also post at or near the best bid, the market-maker's activities would not generally qualify as bona-fide market-making. Moreover, a market-maker that continually executes short sales away from its posted quotes would generally not be considered to be engaging in bona-fide market-making.
BUYINS.NET monitors SBFM market-makers daily for compliance with Fair Market-Making Requirements of Regulation SHO.
About BUYINS.NET
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 34 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. SBFM has paid $1,116 per month to purchase data to be provided in six monthly reports. SBFM has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact:
BUYINS.NET
Thomas Ronk
800-715-9999
tom@buyins.net
http://www.buyins.net

Published at Investorideas.com newswire

Learn more about Sunshine Biopharma Inc. (OTCBB:SBFM): Profile
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensates Investorideas.com for news release publishing and distribution : one hundred thousand 144 shares for three months starting June 26th
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894